Aquestive Therapeutics’ (AQST) Buy Rating Reaffirmed at HC Wainwright

HC Wainwright reissued their buy rating on shares of Aquestive Therapeutics (NASDAQ:AQST) in a research note published on Friday,Benzinga reports. They currently have a $10.00 target price on the stock.

A number of other brokerages have also recently commented on AQST. JMP Securities reaffirmed a “market outperform” rating and issued a $9.00 target price on shares of Aquestive Therapeutics in a report on Tuesday, October 8th. Cantor Fitzgerald assumed coverage on Aquestive Therapeutics in a research report on Tuesday, December 17th. They issued an “overweight” rating and a $17.00 price target for the company. Finally, Leerink Partners lifted their price objective on Aquestive Therapeutics from $12.00 to $13.00 and gave the company an “outperform” rating in a research report on Friday, October 25th. Six equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Buy” and an average price target of $11.00.

Aquestive Therapeutics Stock Performance

AQST stock opened at $3.65 on Friday. The business’s 50-day moving average is $4.71 and its two-hundred day moving average is $4.08. Aquestive Therapeutics has a fifty-two week low of $1.84 and a fifty-two week high of $6.23. The company has a market cap of $332.80 million, a price-to-earnings ratio of -8.11 and a beta of 2.62.

Aquestive Therapeutics (NASDAQ:AQST) last announced its earnings results on Monday, November 4th. The company reported ($0.13) EPS for the quarter, missing analysts’ consensus estimates of ($0.12) by ($0.01). The business had revenue of $13.54 million for the quarter, compared to analyst estimates of $12.69 million. During the same period in the prior year, the company posted ($0.03) earnings per share. Equities analysts predict that Aquestive Therapeutics will post -0.47 earnings per share for the current year.

Institutional Investors Weigh In On Aquestive Therapeutics

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Bank of New York Mellon Corp bought a new position in Aquestive Therapeutics in the 2nd quarter worth approximately $594,000. Financial Advocates Investment Management boosted its position in shares of Aquestive Therapeutics by 70.0% during the second quarter. Financial Advocates Investment Management now owns 34,000 shares of the company’s stock worth $88,000 after acquiring an additional 14,000 shares during the last quarter. Rhumbline Advisers purchased a new position in Aquestive Therapeutics during the second quarter valued at $254,000. Victory Capital Management Inc. purchased a new position in Aquestive Therapeutics during the second quarter valued at $27,000. Finally, PFG Investments LLC increased its holdings in Aquestive Therapeutics by 22.9% in the 2nd quarter. PFG Investments LLC now owns 59,000 shares of the company’s stock valued at $153,000 after acquiring an additional 11,000 shares during the last quarter. 32.45% of the stock is owned by institutional investors.

About Aquestive Therapeutics

Aquestive Therapeutics, Inc operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder.